Jatenzo Cost in Texas (2026): Prices, Insurance, and Savings Options

What Jatenzo Actually Costs at Texas Pharmacies in 2026

The retail cash price for Jatenzo at Texas pharmacies sits at approximately $900 per month in 2026, matching the Tolmar manufacturer list price. That figure reflects a 30-day supply of oral testosterone undecanoate capsules taken twice daily with food. Prices can shift by $50 to $100 depending on the specific pharmacy chain and dosage strength prescribed.

Jatenzo received FDA approval in March 2019 as the first oral testosterone undecanoate product for adult males with conditions associated with a deficiency or absence of endogenous testosterone. The key trial by Swerdloff et al. (2020) enrolled 166 hypogonadal men and demonstrated that 87% of subjects achieved average testosterone concentrations within the normal range (300 to 1,100 ng/dL) by day 90. The twice-daily oral dosing sets Jatenzo apart from injectable testosterone formulations, which require intramuscular or subcutaneous administration every one to two weeks.

Texas ranks among the top five states by TRT prescription volume, according to IQVIA dispensing data. That high demand has not translated into lower retail pricing, however. Without insurance or a manufacturer coupon, Texas patients face the full $900 monthly cost, which adds up to $10,800 per year. Price-comparison tools like GoodRx or RxSaver may occasionally show discounts of 5% to 15% at select Texas pharmacies, but these fluctuate and rarely bring the monthly total below $750.

Texas Medicaid and Jatenzo: Why It Is Not Covered

Texas Medicaid does not cover Jatenzo for the standard indication of male hypogonadism. The Texas Health and Human Services Commission's preferred drug list restricts testosterone replacement therapy coverage, and Jatenzo has not been added to the formulary for this diagnosis code.

This exclusion affects a sizable population. Texas has over 4 million adults enrolled in Medicaid, and the Endocrine Society's 2018 clinical practice guideline estimates that hypogonadism affects 2% to 6% of adult men, with prevalence rising after age 40. For Medicaid-enrolled men diagnosed with testosterone deficiency, the state formulary directs prescribers toward generic injectable testosterone cypionate, which costs $30 to $80 per month at most Texas pharmacies.

Patients who believe they have a clinical need specifically for oral testosterone undecanoate can request a formulary exception through their Medicaid managed care organization. These requests require the prescribing physician to document prior treatment failures with preferred agents and provide clinical justification for the branded oral formulation. Approval rates for such exceptions remain low, based on reporting from Texas managed care plans.

Commercial Insurance Coverage for Jatenzo in Texas

Several major Texas commercial insurers, including Blue Cross Blue Shield of Texas, UnitedHealthcare, and Aetna, may cover Jatenzo with prior authorization. The prior authorization process typically requires documentation of a confirmed diagnosis of hypogonadism (two morning serum testosterone levels below 300 ng/dL), evidence that the patient has tried or cannot use injectable testosterone, and a prescription from an endocrinologist or urologist.

Formulary tier placement varies. When covered, Jatenzo usually lands on Tier 3 (preferred brand) or Tier 4 (non-preferred brand), which means copays in the range of $50 to $150 per month after the deductible is met. Some high-deductible health plans require patients to pay the full $900 until they reach their annual deductible threshold.

The American Urological Association's 2018 guideline on testosterone deficiency supports testosterone replacement for men with symptomatic hypogonadism confirmed by biochemical testing. Having a documented diagnosis that aligns with this guideline strengthens the prior authorization submission. Prescribers in Texas report that including the specific AUA or Endocrine Society guideline citation in the prior authorization letter increases approval likelihood.

For self-funded employer plans in Texas, coverage decisions are made at the employer level, not by the insurance carrier. Patients on self-funded plans should request the specific Summary of Benefits and Coverage document and check whether Jatenzo or oral testosterone undecanoate appears on the formulary by name.

How the Tolmar Savings Card Works for Texas Patients

Tolmar Pharmaceuticals offers a manufacturer savings card for Jatenzo that can reduce out-of-pocket costs for commercially insured patients. Eligible patients may pay as little as $0 per month, with the savings card covering up to a set dollar amount per fill. The card is available through the official Jatenzo website and through prescriber offices.

Key eligibility requirements: the patient must have commercial insurance (not Medicare, Medicaid, TRICARE, or any other government-funded program), must be 18 years or older, and must have a valid Jatenzo prescription. The savings card is not a substitute for insurance. It functions as a secondary payer that covers part or all of the patient's copay, coinsurance, or deductible obligation.

Texas patients should be aware that savings card benefits may have an annual cap. Once the annual maximum is reached, patients revert to their standard insurance cost-sharing. Tolmar may also change the terms of the card at any time without notice. The practical advice here is straightforward: activate the card before your first fill, confirm the annual cap amount with Tolmar's patient support line, and plan for what your costs will look like if you hit that cap mid-year.

Savings cards like this one do not count toward insurance deductibles or out-of-pocket maximums under most commercial plans, a policy known as copay accumulator adjustment. Several major Texas insurers, including Blue Cross Blue Shield of Texas, have adopted accumulator programs. If your plan uses a copay accumulator, the $900 paid by the savings card will not reduce your deductible balance, which means you could face the full copay once the card's annual benefit runs out.

Compounded Oral Testosterone Undecanoate in Texas

Compounded oral testosterone undecanoate is available in Texas through licensed 503A compounding pharmacies. The Texas State Board of Pharmacy regulates these pharmacies under both state law and federal guidelines established by the Drug Quality and Security Act (Section 503A). Texas enforces strict oversight of compounding operations, including regular inspections, ingredient sourcing requirements, and beyond-use dating limits.

The cost difference is substantial. Compounded oral testosterone undecanoate from a 503A pharmacy in Texas can cost significantly less than the branded Jatenzo product. Some compounding pharmacies offer monthly pricing well below the $900 retail price. The exact cost depends on the dosage, the specific pharmacy, and whether the patient is paying cash or using a compounding-friendly insurance plan.

There are clinical trade-offs to consider. Compounded medications do not undergo the same FDA approval process as branded drugs. The Swerdloff et al. trial that established Jatenzo's efficacy and safety profile used the proprietary Self-Emulsifying Drug Delivery System (SEDDS) formulation, which enhances lymphatic absorption and reduces first-pass hepatic metabolism. Compounded versions may use different excipients, different capsule technologies, and different absorption profiles. The FDA has cautioned that compounded drugs are not FDA-approved and may differ in bioavailability from their branded counterparts.

Texas physicians prescribing compounded testosterone undecanoate should monitor serum testosterone levels at 4 to 6 weeks after initiation and adjust dosing based on trough levels, per Endocrine Society recommendations. This monitoring step is especially important with compounded formulations because absorption can vary between products.

Getting Jatenzo Through Telehealth in Texas

Texas permits telehealth prescribing of Jatenzo and other testosterone replacement therapies. The Texas Medical Board allows physicians to prescribe Schedule III controlled substances (which includes testosterone) via telemedicine, provided the prescriber conducts an appropriate medical evaluation and establishes a valid physician-patient relationship.

For a Jatenzo telehealth prescription, a Texas patient typically needs to complete an intake questionnaire, provide recent lab work showing two morning total testosterone levels below 300 ng/dL (drawn before 10 AM), and have a synchronous video or audio visit with a licensed prescriber. Some telehealth platforms operating in Texas will order the initial labs through a partner laboratory network if the patient does not have recent results.

The Endocrine Society guideline recommends against testosterone therapy in men planning fertility in the near term, men with breast or prostate cancer, hematocrit above 50%, untreated severe obstructive sleep apnea, severe lower urinary tract symptoms, or uncontrolled heart failure. A responsible telehealth evaluation should screen for all of these contraindications before prescribing.

Telehealth platforms may bundle the prescription with concierge pricing that includes the medication cost, follow-up labs, and provider visits. These bundled models sometimes offer Jatenzo at a lower effective monthly rate than retail pharmacy pricing, particularly when the platform has negotiated direct pricing with Tolmar or uses a partner pharmacy. Patients should ask for a line-item cost breakdown before committing to a subscription model.

Strategies to Reduce Jatenzo Costs in Texas

Texas patients have several concrete options for lowering their Jatenzo spending. Here they are ranked by typical savings impact.

Switch to generic injectable testosterone cypionate. If the oral delivery route is a convenience preference rather than a medical necessity, generic testosterone cypionate costs $30 to $80 per month and is covered by virtually every Texas insurer, including Medicaid. The FDA label for testosterone cypionate covers the same hypogonadism indication. This is the single largest cost reduction available.

Use the Tolmar savings card. For commercially insured patients, this is the fastest way to reduce Jatenzo copays. Activation takes less than five minutes online, and the card can be presented at any Texas pharmacy.

Request prior authorization proactively. Do not wait for a pharmacy rejection. Have your prescriber submit the prior authorization with complete documentation (two low testosterone labs, symptom inventory, trial history with injectables if applicable) at the time the prescription is written.

Compare pharmacy pricing. Cash prices for Jatenzo can differ by $50 to $100 between Texas pharmacy chains. Independent pharmacies sometimes offer lower pricing than large chains due to different wholesale contracts.

Ask about compounded alternatives. If your prescriber is comfortable with compounded oral testosterone undecanoate and you understand the bioavailability differences, a licensed Texas 503A pharmacy may offer a lower-cost alternative. Confirm the pharmacy's Texas State Board of Pharmacy license before filling.

Check employer plan formulary directly. For patients on self-funded employer plans, the HR benefits team can often provide formulary details faster than the insurance carrier's customer service line.

Cardiovascular Monitoring and Cost Considerations

The Jatenzo FDA label carries a boxed warning about the potential for blood pressure increases. In the Swerdloff et al. trial, systolic blood pressure increased by a mean of 3 to 5 mmHg from baseline, and 7.6% of subjects in the treatment group experienced hypertension as an adverse event. This safety signal means that prescribers should monitor blood pressure at baseline, at 1 month, and at 3 to 6 month intervals during ongoing therapy.

These monitoring visits add to the total cost of Jatenzo therapy. In Texas, an office visit for blood pressure and lab review typically costs $75 to $200 without insurance, and follow-up testosterone, hematocrit, and PSA labs add another $50 to $150 per draw. Patients should factor in two to four monitoring visits per year when calculating their annual out-of-pocket cost for oral TRT.

The American Heart Association has noted that exogenous testosterone may affect cardiovascular risk markers, including hematocrit elevation and changes in lipid profiles. The TRAVERSE trial (Lincoff et al., NEJM 2023), which enrolled 5,246 men aged 45 to 80 with hypogonadism and preexisting or high risk for cardiovascular disease, found that testosterone replacement was noninferior to placebo for major adverse cardiovascular events over a mean follow-up of 33 months. This data has provided some reassurance, though the trial used a transdermal gel, not oral testosterone undecanoate specifically.

For Texas patients with cardiovascular risk factors, the monitoring cadence may need to be more frequent. Dr. Shalender Bhasin, principal investigator of the Testosterone Trials, has stated: "Testosterone treatment should be accompanied by careful cardiovascular monitoring, particularly in older men and those with preexisting risk factors." This guidance applies regardless of the testosterone formulation chosen.

Texas-Specific Regulatory and Pharmacy Considerations

The Texas State Board of Pharmacy maintains an active enforcement posture toward testosterone compounding operations. In 2024, the Board issued updated guidance clarifying that 503A pharmacies compounding testosterone products must maintain patient-specific prescriptions and cannot distribute compounded testosterone on an office-use basis to clinics for general stock. This regulation directly affects availability and pricing at some Texas men's health clinics.

Texas also requires that all testosterone prescriptions (including Jatenzo) be reported to the Texas Prescription Monitoring Program (PMP) database. Prescribers must check the PMP before issuing a new testosterone prescription, and pharmacists must report each dispensing event within one business day. This system does not affect pricing but may add a small processing step that delays first fills at some pharmacies by 24 to 48 hours.

For patients relocating to Texas or splitting time between states, Texas honors valid prescriptions written by physicians licensed in other states, provided the medication is a Schedule III controlled substance and the prescription meets Texas formatting requirements. A Jatenzo prescription from an out-of-state telehealth provider may be filled at a Texas pharmacy if the prescriber holds an active Texas medical license or the prescription was written by a provider with prescriptive authority in the patient's state of residence at the time of the visit.